Hellin A C, Bentires-Alj M, Verlaet M, Benoit V, Gielen J, Bours V, Merville M P
Laboratory of Medical Chemistry and Medical Oncology, University of Liège, Sart-Tilman, Liège, Belgium.
J Pharmacol Exp Ther. 2000 Dec;295(3):870-8.
Daunomycin is a potent inducer of p53 and NF-kappaB transcription factors. It is also able to increase the amount of the p21 cyclin-dependent kinase inhibitor. The human p21 promoter harbors p53-responsive elements and an NF-kappaB binding site. We demonstrated, in human breast and colon carcinoma cells, the binding of NF-kappaB dimers to the kappaB site and the transcriptional activation of the human p21 promoter by daunomycin and by NF-kappaB subunits, thereby confirming the functionality of this kappaB binding site. However, using different tumor cell lines where p53 or NF-kappaB was inactive, we showed that p21 activation and cell cycle arrest induced by daunomycin was p53-dependent and NF-kappaB-independent, whereas daunomycin-induced apoptosis was p53- and NF-kappaB-independent.
柔红霉素是p53和核因子κB转录因子的强效诱导剂。它还能够增加p21细胞周期蛋白依赖性激酶抑制剂的量。人类p21启动子含有p53反应元件和一个核因子κB结合位点。我们在人乳腺癌和结肠癌细胞中证明,核因子κB二聚体与κB位点结合,柔红霉素和核因子κB亚基可使人p21启动子转录激活,从而证实了该κB结合位点的功能。然而,在使用p53或核因子κB无活性的不同肿瘤细胞系时,我们发现柔红霉素诱导的p21激活和细胞周期阻滞是p53依赖性且核因子κB非依赖性的,而柔红霉素诱导的凋亡是p53和核因子κB非依赖性的。